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Abstract
Background: Severe complications, such as eye damage and dysfunciton of salivary glands, have been reported
after radiotherapy among patients with head and neck cancer. Complications such as visual impairment have also
been reported after proton therapy with pencil beam scanning (PBS). In the case of PBS, collimation can sharpen
the penumbra towards surrounding normal tissue in the low energy region of the proton beam. In the current
study, we examined how much the dose to the normal tissue was reduced by when intensity-modulated proton
therapy (IMPT) was performed using a multi-leaf collimator (MLC) for patients with maxillary sinus cancer.
Methods: Computed tomography findings of 26 consecutive patients who received photon therapy at Okayama
University Hospital were used in this study. We compared D2% of the region of interest (ROI; ROI-D2%) and the
mean dose of ROI (ROI-mean) with and without the use of an MLC. The organs at risk (OARs) were the posterior
retina, lacrimal gland, eyeball, and parotid gland. IMPT was performed for all patients. The spot size was
approximately 5–6 mm at the isocenter. The collimator margin was calculated by enlarging the maximum outline
of the target from the beam’s eye view and setting the margin to 6 mm. All plans were optimized with the same
parameters.
Results: The mean of ROI-D2% for the ipsilateral optic nerve was significantly reduced by 0.48 Gy, and the mean of
ROI-mean for the ipsilateral optic nerve was significantly reduced by 1.04 Gy. The mean of ROI-mean to the optic
chiasm was significantly reduced by 0.70 Gy. The dose to most OARs and the planning at risk volumes were also
reduced.
Conclusions: Compared with the plan involving IMPT without an MLC, in the dose plan involving IMPT using an
MLC for maxillary sinus cancer, the dose to the optic nerve and optic chiasm were significantly reduced, as
measured by the ROI-D2% and the ROI-mean. These findings demonstrate that the use of an MLC during IMPT for
maxillary sinus cancer may be useful for preserving vision and preventing complications.
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Background
Cancers of the nasal cavity and paranasal sinuses are un-
common and comprise about approximately 3–5% of all
head and neck cancers. Standard treatment methods for
locally advanced sinonasal carcinomas include surgical re-
section and adjuvant radiation therapy [1, 2]. In addition,
preoperative chemoradiotherapy (CRT) has been success-
ful in achieving a negative surgical margin [3]. At the Oka-
yama University Hospital, preoperative CRT is performed
for T3–4 large maxillary sinus tumors, with a total dose of
66Gy. However, after conventional irradiation, three-
dimensional radiation therapy, and intensity-modulated
radiation therapy (IMRT), serious (grade 3–4) complica-
tions, such as eye damage and salivary gland dysfunction,
have been reported at a rate of 1–24% [4–6]. In addition,
the use of proton beam, heavy particle beam therapy, or
intensity-modulated proton therapy (IMPT)—instead of
three-dimensional radiation therapy—reduces the rate of
complications and improves the local control rate [7].
Treatment with proton beam therapy involves two types
of irradiation methods: passive scattering proton therapy
and IMPT, which is among the more recently developed
irradiation methods. To cover a target during IMPT, each
beam is scanned laterally across the target using magnetic
fields in a technique called pencil beam scanning (PBS).
Similar to IMRT, PBS enables state-of-the-art IMPT that
optimizes all beams to deliver a sufficient dose to the tar-
get. However, serious adverse events such as visual impair-
ment have also been reported after treatment with proton
beams using PBS for head and neck cancers [8]. On the
other hand, during PBS, collimation can reduce the pen-
umbra of the surrounding normal tissue in the low energy
region of the proton beam [9, 10]. Winterhalter et al. re-
ferred to the possibility of improving the dose distribution
in the head region using a multi-leaf collimator (MLC)
[11]. In addition, Moignier et al. reported that IMPT for
head tumors improves the marginal dose while using clin-
ical data [12]. Moreover, Yasui et al. showed that the dose
distribution of peripheral organs at risk (OARs) was im-
proved when IMPT was administered via an aperture,
even in the region including the head and neck area [13].
However, their study was not limited to a single site of
tumor disease. To the best of our knowledge, no previous
study has examined the extent by which the dose to the
normal tissue is reduced by when IMPT with an MLC is
used for a single tumor site in the head and neck region.
Therefore, in this study, we examined by how much the
dose to the normal tissue was reduced by when IMPT
with an MLC is used for maxillary sinus cancer.
Methods
Patients and consent
The imaging results of 26 consecutive patients undergo-
ing photon therapy at the Okayama University Hospital
between September 2009 and March 2017 were used in
this study. All subjects were simulated in the preopera-
tive setting for irradiation and had undergone arterial in-
fusion chemotherapy for maxillary sinus carcinoma, with
the exception of 3 patients in each treatment category
(Table 1). Patients provided written informed consent
for undergoing treatment and were provided the option
to opt out of this study via notifications displayed in the
outpatient ward and on the Okayama University Hospi-
tal’s website. The presiding institutional review board
approved this study (approval number 1712–011).
Target and OARs
Planning computed tomography (CT) scans acquired in
the treatment planning position with 2-mm sliced were
transferred to MIM Maestro, ver. 6.6.7 (Cleveland, Ohio
US) for delineation of the gross tumor volume (GTV)
and OARs and for the planning at risk volumes (PRVs).
The GTV and OARs were contoured by a radiation on-
cologist, with confirmation from two additional
Table 1 Demographic, clinical, and treatment characteristics of
patients (n = 26)
Characteristic N(%)
Gender
Female 5(19%)
Male 21(81%)
Maxillary sinus
Right 13(50%)
Left 13(50%)
Histological type
Squamous cell carcinoma 24(92%)
Spindle cell carcinoma 1(4%)
Small cell carcinoma 1(4%)
T stage
T2 2(8%)
T3 11(42%)
T4 13(50%)
N stage
N- 26(100%)
N+ 0(0%)
Radiotherapy
Preoperative 23(88%)
Definitive 3(12%)
Chemotherapy
No 0(0%)
Yes
Arterial infusion chemotherapy 23(88%)
Other chemotherapy 3(12%)
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specialists in radiation oncology. A margin of 3 mm was
added to the GTV to calculate the clinical target volume
(CTV). The CTV was then corrected for natural
anatomic boundaries such as the bone or air cavities.
Delineated OARs included the brainstem, optic chiasm,
pituitary gland, optic nerve, posterior retina, lacrimal
gland, eyeballs, parotid gland, and cochlea. A 3-mm
margin was added to the brainstem, optic chiasm,
optic nerve, and cochlea to obtain the respective
PRVs [14, 15]. PRVs were not modified even if the
CTV and PRV overlapped.
Robustness
The value of 3 mm was the margin of uncertainty for
patients with head and neck tumors, allowing for
machine variability. The value of 3.5% was the range of
uncertainty resulting from uncertainties in the range
calculation, the acquisition of CT number, and the CT
number-stopping power conversion table [13, 16].
Treatment planning and dose prescription
The pencil beam scanning method was used for all pa-
tients undergoing proton therapy using the system at
our institute (Hitachi, Tokyo, Japan). The proton therapy
system was equipped with an MLC. All IMPT treatment
planning was performed on the RayStation, version 7
(Raysearch Laboratories AB, Stockholm, Sweden). For all
patients, planning was performed with 2 coplanar beams
and 1 non-coplanar beam [17]. The same gantry angle
was used for both sides. For right side tumors, the gantry
angles of coplanar beams were set at 0° and 90°, and the
non-coplanar gantry angle was 45°. For left side tumors,
the gantry angles of coplanar beams were set at 0° and
270°, and the non-coplanar beam angle was 315°. The
radiation therapy dose to the CTV before surgery for
maxillary sinus cancer was 66 Gy in 33 fractions. Dose
computations used a proton pencil beam model with
optimization for intensity-modulated proton fields. The
dose constraints used were based on previous reports
(Table 2) [18].
Spot size and margin of an MLC
An MLC margin was required to assure the marginal
dose of the target. As the spot spacing was affected by
spot size, the spot size was approximately 5–6 mm at the
isocenter. The collimator margin was computed by
expanding the maximum outline of the target from the
beam’s eye view with the margin set to 6 mm [13].
Optimization parameters
All plans were optimized with the same parameters to
evaluate differences due to IMPT with or without an
MLC, i.e., the same constrained optimization functions
for CTV, OARs, and PRV objectives with the related
parameters, the same gantry for with and without an
MLC, as well as the same parameters, as shown in
Table 3. To emphasize the differences in the MLC, the
applied constraints in this study were those that were
not chosen during generation of the clinical treatment
plans.
Plan evaluation
We compared the dose indexes for plans with and with-
out an MLC. We prepared both plans with equal CTV
D95% doses. We examined the relative change of some
dose indexes such as the D2% of the region of interest
(ROI; ROI-D2%) and the mean doses of the ROI (ROI-
mean) of the OARs, PRVs, and irradiation volume (V5 Gy,
V10 Gy, V15 Gy, V20 Gy, and V25 Gy of the ipsilateral
lacrimal gland).
Statistical analysis
We analyzed individual dose volume histograms for both
treatment plans using Wilcoxon rank sum tests, with
p < 0.05 considered statistically significant. Statistical
analyses were performed using SPSS software, version 22
(IBM, NY, USA).
Results
Typical dose distribution and its difference in dose plan-
ning with and without an MLC are shown in Fig. 1. The
IMPT plan using an MLC resulted in a sharp lateral
penumbra, and the dose to the ipsilateral optic nerve
was reduced. The OARs and PRV dose metrics are
shown in Figs. 2 and 3 as boxplots for each patient over-
laid with boxplots summarizing the data. The central
colored line in the boxplots represents the median, with
the edges representing the 25th and 75th percentiles.
The whiskers show the range of data excluding outliers.
The central, dashed black line represents the mean. Wil-
coxon signed rank tests were performed between each
pair of treatment modalities.
Table 2 Dose constraints and recommendations for intracranial
organs at risk when conventional fractionation is used
OAR and PRV Constraints
Optic chiasm Dmax < 54 Gy
Optic nerve Dmax < 54 Gy
Pituitary gland Dmax < 50 Gy
Brainstem Dmax < 54 Gy
Retina Dmax < 45 Gy
Eyeball Dmax < 45 Gy
Lens Dmax < 6 Gy
Lacrimal gland V30 Gy < 50%
Cochlea Dmean 45 Gy
OAR organ at risk, PRV planning organ at risk volume
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Table 3 Parameters
ROI name Description Weight Robust
CTV Min DVH 6600 cGy to 95% volume 50 +
CTV Max DVH 7042 cGy to 10% volume 10 –
CTV Max DVH 7920 cGy to 2% volume 10 –
CTV Min DVH 6138 cGy to 98% volume 10 –
Optic chiasm + 3mm Max DVH 5400 cGy to 2% volume 10 –
Optic chiasm Max DVH 5400 cGy to 2% volume 5 –
Pituitary gland Max DVH 4500 cGy to 2% volume 1 –
Brainstem + 3mm Max DVH 5000 cGy to 2% volume 5 –
Brainstem Max DVH 5000 cGy to 2% volume 2 –
Posterior retina in both eyes Max DVH 4500 cGy to 2% volume 5 –
Parotid gland on both sides Max EUD 3000 cGy 1 –
Optic nerve in both eyes + 3mm Max DVH 5400 cGy to 2% volume 5 –
Optic nerve in both eyes Max DVH 5400 cGy to 2% volume 10 –
Lens in both eyes Max DVH 600 cGy to 2% volume 1 –
Lachrymal gland in both eyes Max EUD 3000 cGy 5 –
Both eyeballs Max DVH 4500 cGy to 2% volume 3 –
Cochlea on both sides Max DVH 4500 cGy to 2% volume 3 –
Cochlea on both sides + 3mm Max DVH 4500 cGy to 2% volume 1 –
Body contour Max DVH 7042 cGy to 2% volume 5 –
ROI region of interest, CTV clinical target volume, DVH dose volume histogram, EUD equivalent uniform dose, Max maximum, Min minimum
Fig. 1 Views of the dose distributions during the treatment of maxillary sinus cancer. MLC, multi-leaf collimator
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The parameters of OARs and PRVs in dose planning
with or without an MLC are shown in Table 4. As
shown in Table 4, the mean of ROI-D2% and ROI-mean of
the ipsilateral optic nerve were significantly reduced in
the group with an MLC. The mean of ROI-mean of the
optic chiasm was also significantly reduced in the MLC
group, as was the mean of ROI-D2% of the ipsilateral
optic nerve, which reduced from 50.06 Gy to 49.58 Gy,
with a difference of 0.48 Gy. Similarly, the mean of ROI-
mean of the ipsilateral optic nerve was reduced from
27.66 Gy to 26.62 Gy, with a difference of 1.04 Gy. In the
optic chiasm, the mean of ROI-mean was reduced from
8.20 Gy to 7.50 Gy, indicating a difference of 0.70 Gy.
Other OARs and PRVs are shown in Table 4. A dose
reduction was observed in most OARs and PRVs, with
the exception of the D2% of the optic chiasm, pituitary
gland, ipsilateral posterior retina, and eyeball, as well as
the ROI-mean of the ipsilateral posterior retina, ipsilateral
eyeball, and contralateral parotid gland.
As shown in Fig. 4, the irradiation volumes of the lac-
rimal gland with and without an MLC were as follows:
V5 Gy, 0.23 cm3 vs. 0.20 cm3, difference = 0.03 cm3, p =
0.080; V10 Gy, 0.11 cm3 vs. 0.08 cm3, difference = 0.03
cm3, p = 0.003; and V15 Gy, 0.05 cm3 vs. 0.20 cm3, differ-
ence = 0.01 cm3, p = 0.007. In general, these data show
significant reductions associated with the use of an MLC
in the low dose area only, while no significant differ-
ences were found above V20 Gy.
Fig. 2 Box and dot plots of OARs and PRVs by ROI-D2%. ROI-D2%, D2% of the region of interest; MLC, multi-leaf collimator; OAR: organ at risk; PRV:
planning at risk volume; IS, ipsilateral side; CS, contralateral side
Fig. 3 Box and dot plots of OARs and PRVs by ROI-mean. ROI-mean, mean dose of region of interest dose; MLC, multi-leaf collimator; OAR: organ at
risk; PRV: planning at risk volume; IS, ipsilateral side; CS, contralateral side
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The beam energy was automatically selected by the
treatment planning device and was 70.70–126.50MeV.
The mean beam monitor unit (MU) used in the plan
was 21,82,193/fraction (range, 12,30,730–38,85,439)
without an MLC and 23,34,309/fraction (range, 13,53,
181–40,76,774) with an MLC. The use of an MLC re-
sulted in an increase in the MU in all cases, increasing
on average by 7% (range, 2–17%).
Discussion
The results of the current study demonstrate that, com-
pared to IMPT without an MLC, IMPT using an MLC
resulted in a significantly lower the mean of ROI-D2% to
the ipsilateral optic nerve, as well as lower the mean of
ROI-mean to the ipsilateral optic nerve and optic chiasm,
while providing an optimal dose to the treatment targets
for maxillary sinus cancer.
Although postoperative CRT is the standard treatment
for T3–4 maxillary sinus cancer, there are also reports
of inoperable cases, surgical refusal, and the use of
preoperative CRT [4, 6, 19]. Multidisciplinary treatment
with surgery, chemotherapy, and radiation therapy is
performed for maxillary sinus cancer [2, 3]. Visual
impairments have been reported as a complication of
surgery and photon therapy for maxillary sinus cancer
on both the ipsilateral and contralateral sides [19]. In re-
cent years, particle beam therapy has been attempted for
paranasal sinus cancers to reduced sever complications.
However, Fukumitsu et al. reported brain necrosis and
optic dysfunction, even with proton beam therapy for
sinus cancer [8]. During proton beam treatment for
ethmoid sinus cancer, which is relatively similar to max-
illary sinus cancer, adverse events include optic
neuropathy and cerebral necrosis [20]. Thus, dose reduc-
tion to normal organs is necessary to avoid complica-
tions such as optic neuropathy and cerebral necrosis.
On phantom experiments, a reduction in penumbra
due to low energy regional collimation with PBS was re-
ported [21]. In the current study, the beam energy was
70.70–126.50MeV. We planned to use low energy and
the use of an MLC should have improved the penumbra
more clearly, and the marginal dose was better and the
dose distribution was improved.
In current study, the dose reductions were small with
and without the use of an MLC. OARs and PRVs dose
in PBS proton therapy will depend on the parameters
used for optimization. These include patient distance,
tumor depth, irradiation angle, PBS beam quality, algo-
rithms for optimization of treatment planning systems,
and the use of optimization and an MLC. The cases in-
cluded in our study were consecutive cases of maxillary
sinus cancer at the Okayama University Hospital. Also,
the size, degree of invasion, and shape of each tumor are
different, all plans are prepared under the same condi-
tions, except for the use of an MLC, to eliminate
planning bias. We speculate that the plan under this
condition was the reason for the small difference of our
result. Better dose distribution may be achieved if IMPT
constraint optimization and gantry angle are fully
considered.
According to Yasui et al. [13], the use of an MLC for
lesions in the head and neck region has led to cases
where the dose to the optic nerve decreased by a few
percent and the dose to the optic chiasm decreased by
up to 32%. However, that study was not focused on a
single disease and the evaluated OARs were different for
Fig. 4 Box and dot plots of the ipsilateral lacrimal gland dose volume metrics. * ; p < 0.05 Significant difference
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each irradiation site. In contrast, the current study
showed that the dose to the optic nerve and lacrimal
gland can be reduced using an MLC during IMPT
among patients with a single disease. In the overall com-
parison of the mean ROI-D2% and ROI-mean with and
without an MLC, the mean of ROI-D2% for the ipsilateral
optic nerve was reduced by 0.48 Gy and the mean of
ROI-mean was reduced by 1.04 Gy. The mean of ROI-
mean to the optic chiasm was reduced by 0.70 Gy.
In previous studies regarding the effect of radiation on
the lacrimal gland, no significant dry eye symptoms were
observed in patients who received a mean dose of < 30Gy
to the lacrimal gland during photon radiation therapy and
these studies have shown symptoms in the all patients
treated with doses > 45Gy and with doses > 57Gy during
photon radiation therapy [22, 23]. Although the lacrimal
gland did not receive a high enough dose to cause compli-
cations when the mean doses were administered with and
without an MLC (5.7 Gy and 6.5 Gy, respectively) in the
current study, the dose of lacrimal gland was decreased
significantly. This finding may be useful when irradiation
is performed near the lacrimal gland.
Yasui et al. showed the utility of the patient-specific
aperture system. In their study, the OAR dose was re-
duced by several percent to several tens of percent
owing to the patient-specific aperture system [13]. We
believe this was the reason why the dose reduction effect
to the surrounding OAR was low in our study compared
to that in the study by Yasui et al. First, it is possible that
the spot size used in our treatment system was smaller
(5–6 mm at the isocenter) than that of their machine,
which was 7.2–11.8 mm at the isocenter. According to
Moteabbed et al., a smaller spot size is associated with a
less effective MLC [24]. Second, in the current study,
PRVs were not modified even if the CTV and PRV over-
lapped to prevent planned bias, which was observed in
several plans. Third, to prevent bias owing to the plan,
the gantry angle and dose constraints were fixed in all
plans.
In the current study, we used the collimating MLC
technique along the largest edge of the tumor. Daniel
et al. reported a dynamic collimation system in which
collimation is performed by moving two blades per layer
with the beam spot [25, 26]. In their method, collimation
can be performed on all layers of the tumor. The pen-
umbra of the beam on the distal side and on the prox-
imal side of the tumor is reduced; it is thought that the
concentration of the proton beam is improved. There-
fore, the dose distribution of the surrounding normal tis-
sue is significantly improved by approximately 13.65%
compared to cases that were treated without the dy-
namic collimation system [12]. Further advances in
therapeutic devices may show potential for improved
dose distribution.
Even if an MLC is used, there are no additional costs
for each patient. In contrast, the use of MLC plans in-
creased the MU by mean of 7% (range, 2–17%). There-
fore, the increase in MU slightly increases the treatment
time. The dose of the ipsilateral eyeball was increased by
the use of an MLC. Doses to the eye and surrounding
normal tissue are issues of optimization and gantry
angle, suggesting that optimization and examination of
angles are necessary for each case.
This study has some limitations, including the rela-
tively small sample size of 26 cases. Moreover, it was not
possible to obtain MR fusion images, and we did not re-
plan treatments as might be performed during adaptive
therapy. Finally, the dose calculation algorithm used in
this study did not include Monte-Carlo simulations.
Conclusion
During IMPT, the use of an MLC for the treatment of
maxillary sinus cancer reduces the dose to the ipsilateral
optic nerve. Also, the dose of most OARs and PRVs
were reduced in the MLC group. In the future, a large-
scale prospective study should be conducted to deter-
mine the effectiveness of the collimation, the results of
which can be used to improve IMPT dose distribution
and thus reduce adverse events.
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